Biotest AG: Slight increase in sales of 2.3% despite difficult market environment
Biotest AG / Key word(s): Preliminary Results
20.02.2012 09:49
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)
Biotest: Slight increase in sales of 2.3% despite difficult market
environment
Dreieich, 20 February 2012. According to preliminary and unaudited figures,
the Biotest Group (Plasma Proteins and Biotherapeutics) recorded sales of
EUR 422.0 million in the financial year 2011, an increase of 2.3% compared
to the previous year (EUR 412.5 million).
Earnings before interest and tax (EBIT) of the Group (Plasma Proteins,
Bio-therapeutics and Corporate) are slightly lower with EUR 41.6 million
compared to the previous year's EBIT of EUR 42.9 million. The reasons for
this were predominantly considerable price reductions for immunoglobulins
and coagulation factors, especially within the international business, as
well as the unabsorbed costs incurred in connection with the expansion of
the production facility in Boca Raton, Florida, USA. Included however is a
contribution from the upfront-payment of the Abbott agreement of EUR 17.4
million.
The earnings after taxes of the Biotest Group with its Continuing
Operations and Discontinued Operation are at EUR 48.1 million in the year
2011. Earnings after taxes of the Discontinued Operation are at EUR 29.4
million. In this amount the net profit from the sale of the Microbiological
Monitoring business is included.
Biotest will publish final results for the Financial Year 2011 on March
22th, 2012, the annual report will be published on the same day. The Annual
General Meeting of Biotest AG will take place on May 10th, 2012 in
Frankfurt a.M.
Biotest Aktiengesellschaft
The Executive Management Board
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of immunology and haematology. In its Plasma Protein segment,
Biotest develops and markets immunoglobulins, coagulation factors and
albumins based on human blood plasma. These are used for diseases of the
immune and haematopoietic systems. In the Biotherapeutic segment, Biotest
researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. Biotest has more than 1,600 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
20.02.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
